PN and PDLLA vs PDRN: What Korea's New Skin-Booster Ingredients Are
Quick Answer
PN (polynucleotide) and PDRN are both mixtures of DNA fragments, and PN is the longer-chain, larger-molecule version. PDLLA is not DNA at all: it is poly-D,L-lactic acid, a biodegradable polylactic acid polymer. So the three names look alike, but they appear differently on an ingredient list and need different checks on the raw material spec sheet.
In Korean clinics, a skin booster is an injectable meant to improve overall skin quality: texture, elasticity and hydration. Three acronyms run through that category: PDRN, PN and PDLLA.
PDRN already crossed over into serums and creams. If a Korean lab or raw material supplier now pitches PN or PDLLA as the next step, know this first: the three names cover two very different materials. Below is what each one is, how it shows up on a label, what the human studies cover, and the spec sheet to ask for before you sample.
Key Takeaways
- PN and PDRN are DNA fragment mixtures, mostly from salmon or trout. PN has the longer chains.
- No agreed molecular weight line separates PN from PDRN, so the supplier's size data matters more than its trade name.
- PDLLA is a biodegradable polymer, not DNA. Its spec sheet reads like a particle spec.
- The published human studies on PN and PDLLA test injections, and many are small. They say nothing direct about a cream.
- In the US, cream copy that promises collagen production or injection-like results reads as a drug claim.
What Are PN, PDLLA and PDRN?
PN (polynucleotide) is a mixture of long DNA fragments, purified from fish such as salmon or trout. PDRN (polydeoxyribonucleotide) is the same kind of DNA in shorter fragments. PDLLA (poly-D,L-lactic acid) is a different material entirely: a biodegradable polymer made from lactic acid.
A 2025 review in Pharmaceutics explains why the two DNA ingredients behave differently (Kim, 2025). PN's longer chains form a viscous, gel-like network, and the review sees it mainly as structural support. PDRN's shorter chains act on adenosine A2A receptors and feed the cell's nucleotide recycling.
PDLLA works by a third route. In clinics it is injected as microspheres. A 2025 expert consensus describes those microspheres as the collagen-stimulating part of a PDLLA and hyaluronic acid injectable (Lau et al., 2025). That is a medical procedure. It tells you what the material does under the skin, not on it.
PN vs PDLLA vs PDRN at a Glance
PN and PDRN share most answers because they are one material at two sizes. PDLLA needs its own column of questions. Read the table row by row before you compare quotes.
| Item | PN | PDRN | PDLLA |
|---|---|---|---|
| What it is | Longer DNA fragments | Shorter DNA fragments | Polylactic acid polymer with D and L forms |
| Original use | Injectable medical devices in Korea, such as skin boosters | Prescription injectable for wound healing and tissue repair in Korea; Placentex in Italy | Injectable biostimulator and skin booster |
| Name on a cosmetic label | A DNA name; "PN" is a supplier term, not an INCI name | Sodium DNA or Hydrolyzed DNA | Polylactic Acid |
| Form to confirm | Powder or solution, and its DNA content | Powder or solution, and its DNA content | Particle powder or dispersion, and its particle size |
| Ask for on the spec | Source species, fragment size data with method, DNA content method, lot certificates | The same four items, measured the same way as the PN you compare it with | Particle size distribution, residual solvent, polymer grade, lot certificates |
The original-use and label rows come from the Pharmaceutics review: in Korea, PDRN is approved as a medicine for graft wounds and tissue regeneration, PN injectables are regulated as medical devices, and PDRN in cosmetics is registered as Sodium DNA or Hydrolyzed DNA.
Why Is the Line Between PN and PDRN So Blurry?
Because nobody has fixed it. The same review notes that no standardized molecular weight thresholds separate PN from PDRN. Manufacturers draw the line with their own processes, and some products labeled PN turned out to contain mostly PDRN on further analysis.
The process names are part of the branding. Mastelli in Italy uses High Purification Technology, and PharmaResearch in Korea uses its DNA fragment Optimizing Technology for both PN and PDRN products. The review adds that the detailed methods remain largely undisclosed, and that some extraction methods leave a broad spread of molecular weights.
So treat the trade name as a starting point, not proof. The K-beauty 2027 ingredient trend forecast on this blog flagged these longer-chain DNA variants. It made the same point: species and molecular weight specification matter more than the name on the INCI list.
"I'm Liz, I run altameet from Manhattan, NYC. When a supplier offers PN as an upgrade, I ask for one document before any price talk: the fragment size data, measured the same way as the PDRN it would replace. If the two sheets cannot be compared, the upgrade is only a name. If you want a quick gut-check on a PN, PDRN or PDLLA pitch, I'll give you 15 minutes free."
The Human Evidence Is Injection Evidence
Published human studies on PN and PDLLA test injections, not creams, and most are small. They show what clinics do with these materials. They do not show what a topical product can claim.
For PN, the clearest trial is a randomized, double-blind, split-face study of 27 people. It compared PN filler injections around the eyes with non-crosslinked hyaluronic acid on the other side (Lee et al., 2020). Overall visual and global improvement scores did not differ significantly between sides. Some instrument readings, such as roughness and pore volume, improved more on the PN side, and no serious adverse events were reported.
Practice has moved faster than trials. A survey of 235 Korean board-certified dermatologists found PN injection widely used as a skin booster, with facial fine lines as the top indication (Rho et al., 2023).
For PDLLA, the human data are thinner. A 2026 split-face pilot study compared PDLLA with calcium hydroxylapatite in three patients, using biopsies taken three months after injection (Kim, 2026). Both materials showed regenerative activity, and the author called for larger, longer studies.
The wider picture matches. A 2024 systematic review of PN in esthetic medicine found nine studies of low and moderate quality, covering 219 patients (Lampridou et al., 2024). It concluded that rigorous, high-quality studies are still needed.
None of these studies tested a cream, so injection results do not carry over to a topical product's claims. In the US, neither PN nor PDLLA is among the filler materials on FDA's page of approved dermal fillers, and cream copy that promises collagen production, regeneration or injection-like results reads as a drug claim, as the PDRN sourcing and FDA guide explains.
What Should a PN Spec Sheet Show?
A PN spec sheet should prove where the DNA came from, how long the fragments are, how much DNA the material holds, and that each lot matches. Without the size data, PN is only a trade name.
- Source species. Salmon and trout dominate today; plant, algae and other sources are still early, per the Pharmaceutics review. Get the species in writing, since it also decides whether a vegan claim is possible.
- Fragment size data. A distribution by base pairs (bp) or molecular weight, with the test method named. A single average hides the spread.
- DNA content and its test method. Ask how the supplier measures DNA in the raw material, so you know what a concentration on the quote actually counts.
- Lot-by-lot certificate of analysis. A certificate of analysis (CoA) is the lab report that comes with each production lot. Ask for several recent lots to see whether size and content hold steady.
Ask the same four questions about any PDRN you compare it with, measured by the same method. Non-salmon sources follow the same logic; The Ordinary's biotech-derived Lacto-PDRN is one example, and its source and its fragment size are still two separate questions. Finally, ask which INCI name goes on your label, since neither PN nor PDRN is one.
Four Checks for a PDLLA Raw Material
PDLLA is a polymer, so its spec sheet reads like a particle spec, not a DNA one. Check particle size, residual solvent, polymer grade and lot consistency before the first sample.
- Particle size distribution. Size changes how the powder feels, disperses and looks in a cream. Ask for the distribution, not one average.
- Residual solvent. If solvents were used to make or process the particles, ask which ones, the residual result and the limit it was tested against.
- Polymer grade. Ask for the grade name, the D to L ratio or molecular weight range the supplier controls, and whether it is a cosmetic grade or one made for medical devices.
- Lot-by-lot certificate of analysis. Same rule as PN: every lot, the same tests, results you can compare.
On the label, PDLLA usually appears under the INCI name Polylactic Acid. That name also covers other polylactic acid forms, so the ingredient list alone does not prove you bought PDLLA. A 2024 review of PDLLA in dermatology stresses the same thing from the clinical side: the polymer's physical and chemical characteristics drive its performance and safety (Lee et al., 2024).
Two more questions belong in the brief. If you also sell in the EU, ask how the particles stand under the EU's rules on intentionally added microplastics; the liposome vs cyclodextrin vs microcapsule guide covers those rules. Delivery systems are a separate decision with their own checks, set out in the spicule skincare spec sheet.
Every other active in the formula needs the same discipline. The heartleaf (Houttuynia cordata) ingredient guide shows the sourcing questions for a botanical active.
PN, PDRN and PDLLA Spec Sheet Checklist
Get the full checklist as a free PDF, straight to your inbox.
Frequently Asked Questions
Is PN the same thing as salmon DNA?
Salmon DNA names the source, not the size. PN and PDRN on the market today come mostly from salmon and trout, so a salmon DNA material can be sold as either one. The fragment size data tells you which.
Is PDLLA the same as the PLLA in Sculptra?
No. Both are polylactic acid polymers, but PLLA uses only the L form of lactic acid, while PDLLA combines the D and L forms. FDA's approved filler materials include PLLA, and that status does not extend to PDLLA.
Is PN stronger than PDRN in a skincare cream?
No public study answers that. The comparisons in the literature come from injections, and the two act differently: PN mainly as structural support, PDRN through adenosine receptors. To back a claim on your own cream, test the finished product; the HRIPT vs clinical vs consumer testing guide explains the options.
Can I put PN or PDLLA on the front of the box?
Yes, as a marketing name, if the material is really in the formula and the wording around it stays cosmetic. The ingredient list still uses the INCI name, so keep the supplier documents that tie the front-of-box name to the INCI line.
By Liz Song, K-beauty sourcing consultant.
